Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.
As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.
Biomedical Advanced Research and Development Authority (BARDA)
BARDA continues to solicit proposals for the development of diagnostic assays and therapeutics for COVID-19 and encourages applicants to participate in a TechWatch meeting prior to submitting a white paper or full proposal in response to its current Broad Agency Announcement
Description: Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7 (AOI 7.7.1 Diagnostic Assay for Human Coronaviruses; AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus; AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies; and AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)). Applications focused on innovations in COVID-19-related manufacturing may be submitted in response to AOI 17 Advanced Manufacturing Technologies.
Topic: Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7; projects to develop COVID-19 therapeutics, including direct-acting antivirals and host-directed therapeutics, may be submitted under AOI 9.2; and projects to develop and demonstrate innovations and enhancements to pharmaceutical manufacturing platforms to support the development of vaccines and therapeutics for COVID-19 can be submitted under AOI 17
Description: BARDA DRIVe’s current EZ-BAA solicitation (BAA-20-100-SOL-0002) includes an Area of Interest (AOI) that is relevant for applicants developing technologies for the early detection of COVID-19 through monitoring of a person’s health status. Through AOI #001 “Early Notification to Act, Control and Treat (ENACT),” DRIVe is seeking technologies and methods to a) identify and characterize biological, behavioral, and physiological signatures that can signal infection or injury before the onset of noticeable symptoms and b) technologies that provide early health status information to medical care providers. Applications may but do not have to focus on COVID-19 as a potential use case.
Topics: Early detection of infection through biological, behavioral, and physiological signatures
Due Dates: Applications are accepted on a rolling basis until 2/3/2023.
Budget: Up to $749,000
While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel. A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.
National Institutes of Health (NIH)
Notices of Special Interest (NOSI)
Multiple NIH Institutes have issued Notices of Special Interest (NOSIs) to provide funding for research topics related to COVID-19. For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.
National Institute on Drug Abuse (NIDA)
Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Description:NIDA has issued this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Proposed revisions may either be within the scope of the existing NIDA grant or expand its scope.
Topics: An extensive list of research areas of interest is provided in the Notice of Special Interest at the above link.
Due Date: Applications will be accepted on a rolling basis until 3/31/2022.
Budget: $100,000 in direct costs per year (maximum project period of 2 years)
National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS)
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
Description: NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions. While there is no obvious indication of adverse events or impacts of the use of COVID-19 vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions.
Topics: This NOSI encourages, but is not limited to, research applications focused on:
- Susceptibility to, prevalence, risk assessment, and clinical management of COVID-19 among patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- The impacts of drugs or other targeted therapies that are used to treat diseases within the mission of NIAMS on susceptibility, severity, and management of COVID-19;
- Health disparities and social/behavioral factors that contribute to risk of infection, organ injury and adverse outcomes in COVID-19 patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- Impact of COVID-19 vaccination of patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- Characterization of long-term post-acute sequelae occurring in recovered COVID-19 patients with co-existing rheumatic, musculoskeletal, and/or skin diseases;
- Characterization of NIAMS-mission related long-term post-acute sequelae (e.g. muscle pain, joint pain, biobehavioral changes, skin rash, arthritis, etc.) occurring in recovered COVID-19 patients.
Due Date: February 5 through November 18, 2021
Budget: Not Specified
National Center for Advancing Translational Sciences (NCATS)
Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.
Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award
US Department of Agriculture (USDA)
National Institute of Food and Agriculture (NIFA)
In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.
Agriculture and Food Research Initiative (AFRI)
Topics: Focus areas of interest include, but are not limited to the following:
- Animal Nutrition, Growth and Lactation (A1231)
- Critical Agricultural Research and Extension (CARE) (A1701)
- Diseases of Agricultural Animals (A1221)
- Food Safety and Defense (A1332)
- Foundational Knowledge of Plant Products (A1103)
- Economics, Markets, and Trade (A1641)
Due Date: Varies by Program
Other US Funding Sources
ImpactAssets and Stop the Spread
Description: Stop the Spread’s COVID Response Program is keenly focused on working with companies and organizations—large and small—to spur development of PPE for both medical and non-medical use, novel testing solutions, widely-accessible therapeutics and digital health solutions to address the needs of underserved communities and vulnerable populations.
- Hyperlocal Support
- Health Services
Due Date: Not Specified
Budget: Not Specified
Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.
Topics: The Accelerator is seeking partners for the following activities:
- Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
- Developing drugs or monoclonal antibodies that pass initial screening.
- Scaling up production and commercialization of successful drugs and monoclonal antibodies.
Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000
Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.
Topics: All COVID-19 related science
Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 – $500,000
Global Innovation Fund
Description: The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people, i.e., those living on less than $5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.
Topics: Innovations to assist with COVID-19 response and related issues affecting people living on less than $5 a day in developing countries.
Due Dates: Applications are accepted on a rolling basis
Budget: $50,000 to $15,000,000 depending upon project stage and needs. Grants are available to for-profit companies where appropriate, but other forms of investment are also used.